Starting dose and escalation decisions
Safety results and limitations imposed by the protocol were the primary consideration when deciding on the starting dose and subsequent dose for the next cohort. To calculate the starting dose, the no‐observed‐adverse‐effect level from Day‐28 dog toxicokinetic study was used for planned ceiling exposure and dose level. The values were C